Table 6.
Trial | NB79 | NB82 | NB85 | NB90 | NB97 | NB04 | All |
---|---|---|---|---|---|---|---|
N | 46 | 47 | 91 | 235 | 250 | 364 | 1019 |
Renal impairment | 0 | 2.1 | 4.4 | 19.6 | 13.2 | 4.7 | 9.9 |
Thyroid dysfunction | 0 | 0 | 3.3 | 4.7 | 10 | 16.2 | 9.6 |
Hearing loss | 0 | 0 | 1.1 | 3.8 | 8.4 | 10.2 | 6.7 |
Second malignancya | 0 | 0 | 1.1 | 8.9 | 1.2 | 1.9 | 3.1 |
Growth retardation | 0 | 4.3 | 2.2 | 4.7 | 2 | 1.9 | 2.6 |
Hepatopathy | 0 | 0 | 0 | 3 | 1.6 | 4.1 | 2.6 |
Spine deformaties | 0 | 0 | 2.2 | 4.7 | 1.6 | 0.8 | 2 |
Cardiovascular dysfunction | 0 | 2.1 | 1.1 | 2.1 | 1.6 | 0.8 | 1.4 |
Peripheral neuropathy | 0 | 0 | 0 | 0.4 | 0.8 | 0.5 | 0.5 |
Data are presented as %
aSecond malignancies without time restrictions: any time after diagnosis (median time of observed cases 70 months, minimum 12 months, maximum 253 months)